European research project T-Control develops new cell therapy strategies to treat complications after hematopoietic stem cell transplantation (HSCT)
With T-Cells Against Blood Cancer
The numbers of patients with high-risk hematological malignancies like leukemia or myeloma are rapidly increasing and cell therapies such as bone marrow transplants are currently applied in more than 25,000 patients per year Europe-wide. Cell therapy, in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), is the only curative treatment for such high-risk hematological malignancies. Unfortunately, whilst these treatments are presently the best chance of a cure, they involve the risk of life-threatening complications such as, return of the disease, vulnerability to infections and, Graft versus Host Disease (GvHD), where the cells from the donor attack tissues from the patient.
Maximise response rates, minimise side effects
Thus, the pan-European collaborative research project T-Control is formed to develop new cell therapy strategies to combat these complications in transplanted patients. The T-Control consortium will explore how white blood cells can help treating transplanted patients with different cellular products specifically designed to fight infections, relapse or GvHD.
New hope for blood cancer patients
The main objectives of T-Control are the clinical development of Streptamer- based cell selection processes and their corresponding cell products. The different cellular products will be a multi virus- and a tumor-specific T-cell product, to boost immune function post-transplant for the treatment of infections and residual/recurrent tumor cells after HSCT. In addition, a primary regulatory T-cell product will be developed to suppress the immune function post-transplant for the treatment of GvHD after HSCT.